{
  "PMC": "6275926",
  "DOI": "10.2478/s11658-009-0011-7",
  "PMID": "19238334",
  "PMCID": "PMC6275926",
  "title": "The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).",
  "year": 2009,
  "source_url": "https://europepmc.org/article/PMC/PMC6275926",
  "source": "MED",
  "abstract_text": "Several studies have reported different expression levels of certain genes in NSCLC, mostly related to the stage and advancement of the tumours. We investigated 65 stage I-III NSCLC tumours: 32 adenocarcinomas (ADC), 26 squamous cell carcinomas (SCC) and 7 large cell carcinomas (LCC). Using the real-time reverse transcription polymerase chain reaction (RT-PCR), we analysed the expression of the COX-2, hTERT, MDM2, LATS2 and S100A2 genes and researched the relationships between the NSCLC types and the differences in expression levels. The differences in the expression levels of the LATS2, S100A2 and hTERT genes in different types of NSCLC are significant. hTERT and COX-2 were over-expressed and LATS2 under-expressed in all NSCLC. We also detected significant relative differences in the expression of LATS2 and MDM2, hTERT and MDM2 in different types of NSCLC. There was a significant difference in the average expression levels in S100A2 for ADC and SCC. Our study shows differences in the expression patterns within the NSCLC group, which may mimic the expression of the individual NSCLC type, and also new relationships in the expression levels for different NSCLC types.",
  "full_text": "Cell Mol Biol Lett Cell. Mol. Biol. Lett Cellular & Molecular Biology Letters 1425-8153 1689-1392 SP Versita Heidelberg 6275926 19238334 11 10.2478/s11658-009-0011-7 Research Article The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC) Stražišar Mojca Mlakar Vid Glavač Damjan 386 1 543 7180 386 1 543 43 7101 damjan.glavac@mf.uni-lj.si grid.8954.0 0000000107216013 Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia 23 2 2009 9 2009 14 3 442 456 23 4 2008 13 2 2009 © © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009 Several studies have reported different expression levels of certain genes in NSCLC, mostly related to the stage and advancement of the tumours. We investigated 65 stage I-III NSCLC tumours: 32 adenocarcinomas (ADC), 26 squamous cell carcinomas (SCC) and 7 large cell carcinomas (LCC). Using the real-time reverse transcription polymerase chain reaction (RT-PCR), we analysed the expression of the COX-2, hTERT, MDM2, LATS2 and S100A2 genes and researched the relationships between the NSCLC types and the differences in expression levels. The differences in the expression levels of the LATS2, S100A2 and hTERT genes in different types of NSCLC are significant. hTERT and COX-2 were over-expressed and LATS2 under-expressed in all NSCLC. We also detected significant relative differences in the expression of LATS2 and MDM2, hTERT and MDM2 in different types of NSCLC. There was a significant difference in the average expression levels in S100A2 for ADC and SCC. Our study shows differences in the expression patterns within the NSCLC group, which may mimic the expression of the individual NSCLC type, and also new relationships in the expression levels for different NSCLC types. Key words COX-2 hTERT MDM2 LATS2 S100A2 RT-PCR Expression issue-copyright-statement © © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009 Abbreviations used ADC adenocarcinoma CDK2 cyclin-dependent kinase 2 cDNA complementary DNA COX-2 cyclooxygenase 2 C T cycle threshold DNA deoxyribonucleic acid GAPDH glyceraldehyde-3-phosphate dehydrogenase hTERT human telomerase reverse transcriptase IHC immunohistochemistry LATS2 homolog of large tumour suppressor 2, Drosophilae LCC large cell carcinoma MDM2 mouse double minute 2 homolog mRNA messenger RNA NSCLC non-small cell lung cancer p21 cyclin-dependent kinase inhibitor 1A p53 tumour protein p53 PCR polymerase chain reaction pTNM pathological tumour-node-metastasis RB retinoblastoma RNA ribonucleic acid r s Spearman’s rank correlation coefficient RT-PCR real time PCR S100A2 S100 calcium binding protein A2 SCC squamous cell carcinoma References 1. Sekido Y. Fong K.M. Minna J.D. Molecular genetics of lung cancer Annu. Rev. Med. 2003 54 73 87 10.1146/annurev.med.54.101601.152202 12471176 2. Wang L. Soria J.C. Kemp B.L. Liu D.D. Mao L. Khuri F.R. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer Clin. Cancer. Res. 2002 8 2883 2889 12231532 3. Kim N.W. Piatyszek M.A. Prowse K.R. Harley C.B. West M.D. Ho P.L. Coviello G.M. Wright W.E. Weinrich S.L. Shay J.W. Specific association of human telomerase activity with immortal cells and cancer Science 1994 266 2011 2015 10.1126/science.7605428 7605428 4. Hiyama K. Hiyama E. Ishioka S. Yamakido M. Inai K. Gazdar A.F. Piatyszek M.A. Shay J.W. Telomerase activity in small-cell and nonsmall-cell lung cancers J. Natl. Cancer. Inst. 1995 87 895 902 10.1093/jnci/87.12.895 7666478 5. Lantuéjoul S. Salon C. Soria J.C. Brambilla E. Telomerase expression in lung preneoplasia and neoplasia Int. J. Cancer. 2007 120 1835 1841 10.1002/ijc.22473 17311257 6. Komiya T. Kawase I. Nitta T. Yasumitsu T. Kikui M. Fukuoka M. Nakagawa K. Hirashima T. Prognostic significance of hTERT expression in non-small cell lung cancer Int. J. Oncol. 2000 16 1173 1177 10811992 7. Lantuejoul S. Soria J.C. Moro-Sibilot D. Morat L. Veyrenc S. Lorimier P. Brichon P.Y. Sabatier L. Brambilla C. Brambilla E. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours Br. J. Cancer 2004 90 1222 1229 10.1038/sj.bjc.6601643 15026805 8. Tazawa R. Xu X.-M. Wu K.K. Wang L.-H. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene Biochem. Biophys. Res. Commun. 1994 203 190 199 10.1006/bbrc.1994.2167 8074655 9. Castelao J.E. Bart R.D. III DiPerna C.A. Sievers E.M. Bremner R.M. Lung cancer and cyclooxygenase-2 Ann. Thorac. Surg. 2003 76 1327 1335 10.1016/S0003-4975(03)00334-5 14530048 10. Laga A.C. Zander D.S. Cagle P.T. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer Arch. Pathol. Lab. Med. 2005 129 1113 1117 16119982 11. Wolff H. Saukkonen K. Anttila S. Karjalainen A. Vainio H. Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma Cancer Res. 1998 58 4997 5001 9823297 12. Hida T. Yatabe Y. Achiwa H. Muramatsu H. Kozaki K. Nakamura S. Ogawa M. Mitsudomi T. Sugiura T. Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas Cancer Res. 1998 58 3761 3764 9731479 13. Hastürk S. Kemp B. Kalapurakal S.K. Kurie J.M. Hong W.K. Lee J.S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma Cancer 2002 94 1023 1031 10.1002/cncr.10262 11920472 14. Ermert L. Dierkes C. Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors Clin. Cancer Res. 2003 9 1604 1610 12738712 15. Fang H.Y. Lin T.S. Lin J.P. Wu Y.C. Chow K.C. Wang L.S. Cyclooxygenase-2 in human non-small cell lung cancer Eur. J. Surg. Oncol. 2003 29 171 177 10.1053/ejso.2002.1316 12633561 16. Brabender J. Park J. Metzger R. Schneider P.M. Lord R.V. Holscher A.H. Danenberg K.D. Danenberg P.V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer Ann. Surg. 2002 235 440 443 10.1097/00000658-200203000-00017 11882767 17. Achiwa H. Yatabe Y. Hida T. Kuroishi T. Kozaki K. Nakamura S. Ogawa M. Sugiura T. Mitsudomi T. Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas Clin. Canc. Res. 1999 5 1001 1005 18. Lu C. Soria J.C. Tang X. Xu X.C. Wang L. Mao L. Lotan R. Kemp B. Bekele B.N. Feng L. Hong W.K. Khuri F.R. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers J. Clin. Oncol. 2004 22 4575 4583 10.1200/JCO.2004.01.091 15542809 19. Gorgoulis V.G. Zacharatos P. Kotsinas A. Mariatos G. Liloglou T. Vogiatzi T. Foukas P. Rassidakis G. Garinis G. Ioannides T. Zoumpourlis V. Bramis J. Michail P.O. Asimacopoulos P.J. Field J.K. Kittas C. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs) Mol. Med. 2000 3 208 237 20. Eymin B. Leduc C. Coll J.L. Brambilla E. Gazzeri S. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice Oncogene 2003 22 1822 1835 10.1038/sj.onc.1206303 12660818 21. Sun Y. p53 and its downstream proteins as molecular targets of cancer Mol. Carcinog. 2006 45 409 415 10.1002/mc.20231 16652354 22. Sdek P. Ying H. Chang D.L.F. Qiu W. Zheng H. Touitou R. Allday M.J. Xiao Z.-X.J. MDM2 promotes proteasome-dependent ubiquitinindependent degradation of retinoblastoma protein Mol. Cell 2005 20 699 708 10.1016/j.molcel.2005.10.017 16337594 23. Uchida C. Miwa S. Kitagawa K. Hattori T. Isobe T. Otani S. Oda T. Sugimura H. Kamijo T. Ookawa K. Yasuda H. Kitagawa M. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation EMBO J. 2005 24 160 169 10.1038/sj.emboj.7600486 15577944 24. Giono L.E. Manfredi J.J. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest Mol. Cell. Biol. 2007 27 4166 4178 10.1128/MCB.01967-06 17371838 25. Duan W. Gao L. Wu X. Zhang Y. Otterson G.A. Villalona-Calero M.A. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells Exp. Cell. Res. 2006 312 3370 3378 10.1016/j.yexcr.2006.07.005 16934800 26. Momand J. Jung D. Wilczynski S. Niland J. The MDM2 gene amplification database Nucleic Acids Res. 1998 26 3453 3459 10.1093/nar/26.15.3453 9671804 27. Wang Y.C. Lin R.K. Tan Y.H. Chen J.T. Chen C.Y. Wang Y.C. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer J. Clin. Oncol. 2005 23 154 164 10.1200/JCO.2005.03.139 15625370 28. Ko J.L. Cheng Y.W. Chang S.L. Su J.M. Chen C.Y. Lee H. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer Int. J. Cancer 2000 89 265 270 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N 10861503 29. Li Y. Pei J. Xia H. Ke H. Wang H. Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition Oncogene 2003 22 4398 4405 10.1038/sj.onc.1206603 12853976 30. McPherson J.P. Tamblyn L. Elia A. Migon E. Shehabeldin A. Matysiak-Zablocki E. Lemmers B. Salmena L. Hakem A. Fish J. Kassam F. Squire J. Bruneau B.G. Hande M.P. Hakem R. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity EMBO J. 2004 23 3677 3688 10.1038/sj.emboj.7600371 15343267 31. Ke H. Pei J. Ni Z. Xia H. Qi H. Woods T. Kelekar A. Tao W. Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L) Exp. Cell. Res. 2004 298 329 338 10.1016/j.yexcr.2004.04.031 15265683 32. Aylon Y. Michael D. Shmueli A. Yabuta N. Nojima H. Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization Genes Dev. 2006 20 2687 2700 10.1101/gad.1447006 17015431 33. Voorhoeve P.M. le Sage C. Schrier M. Gillis A.J. Stoop H. Nagel R. Liu Y.P. van Duijse J. Drost J. Griekspoor A. Zlotorynski E. Yabuta N. De Vita G. Nojima H. Looijenga L.H. Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors Cell 2006 124 1169 1181 10.1016/j.cell.2006.02.037 16564011 34. Abe Y. Ohsugi M. Haraguchi K. Fujimoto J. Yamamoto T. LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and spindle organization during mitosis FEBS Lett. 2006 580 782 788 10.1016/j.febslet.2005.12.096 16413547 35. Mueller A. Schafer B.W. Ferrari S. Weibel M. Makek M. Hochli M. Heizmann C.W. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity J. Biol. Chem. 2005 280 29186 29193 10.1074/jbc.M505000200 15941720 36. Tsai W.C. Tsai S.T. Jin Y.T. Wu L.W. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma Mol. Cancer Res. 2006 4 539 547 10.1158/1541-7786.MCR-05-0266 16908593 37. Feng G. Xu X. Youssef E.M. Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis Cancer Res. 2001 61 7999 8004 11691825 38. Smith S.L. Gugger M. Hoban P. Ratschiller D. Watson S.G. Field J.K. Betticher D.C. Heighway J. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas Br. J. Cancer 2004 91 1515 1524 15467767 39. Wang H. Zhang Z. Li R. Ang K.K. Zhang H. Caraway N.P. Katz R.L. Jiang F. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer Int. J. Cancer 2005 116 285 290 10.1002/ijc.21035 15800916 40. Diederichs S. Bulk E. Steffen B. Ji P. Tickenbrock L. Lang K. Zänker K.S. Metzger R. Schneider P.M. Gerke V. Tomas M. Berdel W.E. Serve H. Müller-Tidow C. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer Cancer Res. 2004 64 5564 5569 10.1158/0008-5472.CAN-04-2004 15313892 41. Nishimura G. Yanoma S. Mizuno H. Kawakami K. Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells Jpn. J. Cancer Res. 1999 90 1152 1162 10595745 42. Lönnroth C. Andersson M. Lundholm K. Indomethacin and telomerase activity in tumor growth retardation Int. J. Oncol. 2001 18 929 937 11295037 43. Deng W.G. Kawashima H. Wu G. Jayachandran G. Xu K. Minna J.D. Roth J.A. Ji L. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells Cancer Res. 2007 67 709 717 10.1158/0008-5472.CAN-06-3463 17234782 44. Ashcroft M. Vousden K.H. Regulation of p53 stability Oncogene 1999 18 7637 7643 10.1038/sj.onc.1203012 10618703 45. Takahashi Y. Miyoshi Y. Takahata C. Irahara N. Taguchi T. Tamaki Y. Noguchi S. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers Clin. Cancer Res. 2005 15 1380 1385 10.1158/1078-0432.CCR-04-1773 46. Takahashi Y. Miyoshi Y. Morimoto K. Taguchi T. Tamaki Y. Noguchi S. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers J. Cancer Res. Clin. Oncol. 2007 133 501 509 10.1007/s00432-007-0194-0 17297610 47. Duale N. Lindeman B. Komada M. Olsen A.K. Andreassen A. Soderlund E.J. Brunborg G. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles Mol. Cancer 2007 6 53 10.1186/1476-4598-6-53 17711579 48. Jiang Z. Li X. Hu J. Zhou W. Jiang Y. Li G. Lu D. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma Neurosci. Res. 2006 56 450 458 10.1016/j.neures.2006.09.006 17049657 49. Jiménez-Velasco A. Román-Gómez J. Agirre X. Barrios M. Navarro G. Vázquez I. Prósper F. Torres A. Heiniger A. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia Leukemia 2005 19 2347 2350 10.1038/sj.leu.2403974 16208412 50. Matsubara D. Niki T. Ishikawa S. Goto A. Ohara E. Yokomizo T. Heizmann C.W. Aburatani H. Moriyama S. Moriyama H. Nishimura Y. Funata N. Fukayama M. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes Cancer Sci. 2005 96 844 857 10.1111/j.1349-7006.2005.00121.x 16367903 51. Soria J.C. Xu X. Liu D.D. Lee J.J. Kurie J. Morice R.C. Khuri F. Mao L. Hong W.K. Lotan R. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers J. Natl. Cancer Inst. 2003 95 165 168 10.1093/jnci/95.2.165 12529350 52. Chen H.H. Yu C.H. Wang J.T. Liu B.Y. Wang Y.P. Sun A. Tsai T.C. Chiang C.P. Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan Oral Oncol. 2007 43 122 129 10.1016/j.oraloncology.2006.01.011 16798059 53. Yim H.W. Slebos R.J. Randell S.H. Umbach D.M. Parsons A.M. Rivera M.P. Detterbeck F.C. Taylor J.A. Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells Cancer Lett. 2007 246 24 33 10.1016/j.canlet.2006.01.023 16517060 54. Mittelstrass K. Sauter W. Rosenberger A. Illig T. Timofeeva M. Klopp N. Dienemann H. Meese E. Sybrecht G. Woelke G. Cebulla M. Degen M. Morr H. Drings P. Groeschel A. Kreymborg K.G. Haeussinger K. Hoeffken G. Schmidt C. Jilge B. Schmidt W. Ko Y.D. Taeuscher D. Chang-Claude J. Wichmann H.E. Bickeboeller H. Risch A. Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene BMC Cancer 2008 23 113 10.1186/1471-2407-8-113",
  "plain_text": "Several studies have reported different expression levels of certain genes in NSCLC, mostly related to the stage and advancement of the tumours. We investigated 65 stage I-III NSCLC tumours: 32 adenocarcinomas (ADC), 26 squamous cell carcinomas (SCC) and 7 large cell carcinomas (LCC). Using the real-time reverse transcription polymerase chain reaction (RT-PCR), we analysed the expression of the COX-2, hTERT, MDM2, LATS2 and S100A2 genes and researched the relationships between the NSCLC types and the differences in expression levels. The differences in the expression levels of the LATS2, S100A2 and hTERT genes in different types of NSCLC are significant. hTERT and COX-2 were over-expressed and LATS2 under-expressed in all NSCLC. We also detected significant relative differences in the expression of LATS2 and MDM2, hTERT and MDM2 in different types of NSCLC. There was a significant difference in the average expression levels in S100A2 for ADC and SCC. Our study shows differences in the expression patterns within the NSCLC group, which may mimic the expression of the individual NSCLC type, and also new relationships in the expression levels for different NSCLC types."
}
